Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby A Eyre

Showing results (81-90 of 119) with videos related to

Pageof 12
Sort By:
British Journal of Haematology|February 23, 2021
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patientsRory McCulloch, David Lewis, Nicola Crosbie, et al.
British Journal of Haematology|April 2, 2020
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survivalNicolás Martinez-Calle, Edward Poynton, Alia Alchawaf, et al.
Blood Advances|September 11, 2020
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphomaStephen Booth, Hannah Plaschkes, Amy A Kirkwood, et al.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Blood Advances|November 15, 2023
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experienceRohan Shotton, Rachel Broadbent, Alia Alchawaf, et al.
British Journal of Haematology|October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Hematology (Amsterdam, Netherlands)|June 6, 2022
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world studyFaouzi Djebbari, Alexandros Rampotas, Grant Vallance, et al.
British Journal of Haematology|May 7, 2021
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysisAlexandros Rampotas, Matthew R Wilson, Oliver Lomas, et al.
British Journal of Haematology|June 13, 2024
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapyYeong Jer Lim, Victoria Ward, Anthony Brown, et al.
Leukemia & Lymphoma|October 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphomaGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Pageof 12

Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
British Journal of Haematology|February 23, 2021
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patientsRory McCulloch, David Lewis, Nicola Crosbie, et al.
British Journal of Haematology|April 2, 2020
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survivalNicolás Martinez-Calle, Edward Poynton, Alia Alchawaf, et al.
Blood Advances|September 11, 2020
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphomaStephen Booth, Hannah Plaschkes, Amy A Kirkwood, et al.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Blood Advances|November 15, 2023
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experienceRohan Shotton, Rachel Broadbent, Alia Alchawaf, et al.
British Journal of Haematology|October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Hematology (Amsterdam, Netherlands)|June 6, 2022
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world studyFaouzi Djebbari, Alexandros Rampotas, Grant Vallance, et al.
British Journal of Haematology|May 7, 2021
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysisAlexandros Rampotas, Matthew R Wilson, Oliver Lomas, et al.
British Journal of Haematology|June 13, 2024
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapyYeong Jer Lim, Victoria Ward, Anthony Brown, et al.
Leukemia & Lymphoma|October 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphomaGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Pageof 12